Black Rock Inc. Longeveron Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.25 - $2.51 $172 - $346	-138 Reduced 0.12%	111,700 $151,000
Q3 2023 Nov 13, 2023	SELL	$2.15 - $3.59 $1,038 - $1,733	-483 Reduced 0.43%	111,838 $261,000
Q2 2023 Aug 11, 2023	BUY	$2.52 - $4.0 $5,171 - $8,208	2,052 Added 1.86%	112,321 $379,000
Q1 2023 May 12, 2023	BUY	$2.66 - $4.36 $861 - $1,412	324 Added 0.29%	110,269 $294,000
Q4 2022 Feb 13, 2023	BUY	$2.81 - $4.3 $606 - $928	216 Added 0.2%	109,945 $354,000

Q3 2022 Nov 14, 2022	SELL	$3.97 - $7.38 $1,071 - $1,992	-270 Reduced 0.25%	109,729 $406,000
Q2 2022 Aug 12, 2022	BUY	$5.93 - $15.61 $160,169 - $421,626	27,010 Added 32.55%	109,999 $652,000
Q4 2021 Feb 10, 2022	BUY	$2.92 - $42.3 $242,327 - $3.51 Million	82,989 New	82,989 $1 Million

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $9.54M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.